Have a feature idea you'd love to see implemented?
Let us know!
NVAX Novavax Inc
Price (delayed)
$9.79
Market cap
$1.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.69
Enterprise value
$1.11B
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III
Highlights
NVAX's quick ratio has surged by 65% year-on-year and by 47% since the previous quarter
Novavax's EPS has surged by 63% YoY and by 14% QoQ
The revenue has contracted by 38% YoY
NVAX's gross profit is down by 29% YoY
Key stats
What are the main financial stats of NVAX
Market
Valuations
Earnings
Shares outstanding
160.09M
Market cap
$1.57B
Enterprise value
$1.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.12
Revenue
$987.67M
EBIT
-$273.65M
EBITDA
-$228.25M
Free cash flow
-$23.57M
Per share
Balance sheet
Liquidity
EPS
-$2.69
Free cash flow per share
-$0.16
Book value per share
-$3.07
Revenue per share
$6.66
TBVPS
$11.43
Total assets
$1.82B
Total liabilities
$2.25B
Debt
$233.25M
Equity
-$431.71M
Working capital
$45.56M
Debt to equity
-0.54
Current ratio
1.04
Quick ratio
0.94
Net debt/EBITDA
2
Margins
Efficiency
Dividend
EBITDA margin
-23.1%
Gross margin
63.6%
Net margin
-29.8%
Operating margin
-29.7%
Return on assets
-17.8%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-41.4%
Return on sales
-27.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVAX stock price
How has the Novavax stock price performed over time
Intraday
-2.78%
1 week
-2.1%
1 month
-22.49%
1 year
50.15%
YTD
103.96%
QTD
-22.49%
Financial performance
How have Novavax's revenue and profit performed over time
Revenue
$987.67M
Gross profit
$628.31M
Operating income
-$293.03M
Net income
-$294.33M
Gross margin
63.6%
Net margin
-29.8%
Novavax's operating income has soared by 53% YoY and by 26% from the previous quarter
Novavax's net income has increased by 50% YoY and by 26% from the previous quarter
The revenue has contracted by 38% YoY
NVAX's gross profit is down by 29% YoY
Growth
What is Novavax's growth rate over time
Valuation
What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.12
Novavax's EPS has surged by 63% YoY and by 14% QoQ
Novavax's equity has surged by 50% QoQ and by 43% YoY
NVAX's P/S is 88% below its 5-year quarterly average of 12.9 but 68% above its last 4 quarters average of 0.9
The revenue has contracted by 38% YoY
Efficiency
How efficient is Novavax business performance
NVAX's return on assets is up by 41% year-on-year and by 28% since the previous quarter
Novavax's return on sales has increased by 28% QoQ and by 22% YoY
Dividends
What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVAX.
Financial health
How did Novavax financials performed over time
Novavax's total assets is 19% lower than its total liabilities
NVAX's quick ratio has surged by 65% year-on-year and by 47% since the previous quarter
The current ratio has increased by 46% year-on-year and by 16% since the previous quarter
Novavax's debt is 154% higher than its equity
NVAX's debt to equity has dropped by 108% since the previous quarter and by 108% year-on-year
Novavax's equity has surged by 50% QoQ and by 43% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.